Brief: Serb Pharmaceuticals To Acquire European And MENA Rights To Idefirix From Hansa Biopharma
19/05/2026 06:37
May 19 (Reuters) - SERB Pharmaceuticals: SERB PHARMACEUTICALS TO ACQUIRE EUROPEAN AND MENA RIGHTS TO IDEFIRIX® (IMLIFIDASE) FROM HANSA BIOPHARMA FOR €115 MILLION Source text: ID:nGNX7zcJr6 Further company coverage: HNSA.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS